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This document has been prepared as a pre reading material to the workshop ‘Examining the 
equity of global health interventions using infectious disease transmission models’, BMA 
House (British Medical Association), Tavistock Square, London, 26-27 March 2018.  
 
During this workshop, we will present and expand on concepts, methods, and 
considerations. This document and the discussions during the workshop aim to inform the 
Reference Case for Economic Evaluation in Global Health.  
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Summary 
There is significant potential in using disease transmission models and economic evaluation 
frameworks to consider the equity of alternative courses of action in global health. The 
consideration of who is more or less advantaged, and how best to address these differences 
when they are unfair, is central to the rationale for the global health sector. Yet, economic 
evaluation typically assesses policy alternatives in terms of aggregate costs and consequences, 
not including information on who suffers costs and who gains. Further, it may be important to 
the policy question to consider the distribution of externalities in addition to direct costs and 
consequences. Disease transmission models are increasingly used for economic evaluation and 
are a suitable tool to simulate the externality effects of infectious disease interventions, 
accounting for changes in risk to others when an individual benefits from disease treatment or 
prevention.  
 
In this report, we examine the interface of these three domains: equity, economic evaluation, 
and disease transmission modelling. First, we present a descriptive review of concepts and 
methodological approaches and, second, an exploration of key methodological considerations 
when including equity into economic evaluations using transmission models.  
 
Part 1: Review of equity, economic evaluation, and disease transmission modelling 
Any statement about equity includes a value judgement. We describe a range of concepts 
guiding this judgement including: egalitarianism, the decent minimum, Rawlsian maximin, 
capability theory, and utilitarianism. We then define four methodological families when 
including equity in priority setting: i) outcome weighting, ii) additional evaluative criteria, iii) 
quantification of any trade-offs between efficiency and equity, and iv) inclusion of qualitative 
equity-related evidence alongside quantitative results. We describe the methods developed in 
each group and present expand on the approaches with recent applications in low and middle 
income countries, for example extended cost effectiveness analysis, distributional cost 
effectiveness analysis, and multi-criteria decision analysis.  
 
Part 2: Key methodological considerations 
Building on the methods and concepts described in part 1, we discuss and present a draft 
checklist of methodological considerations for analysts who wish to incorporate equity in 
mathematical models used for economic evaluation. These recommendations move 
sequentially through four key aspects in this space i) defining the policy question, ii) choice of 
evaluation framework, iii) model structure, and iv) data requirements. First, considering the 
equity-related decision problems faced in global health, we note that the perspective of the 
decision maker will be critical to the definition of scope in an equity-informed analysis. 
However, while some decision problems are explicit in their equity concerns, in other cases 
there is an interest in equity but no prior specification. Second, we consider the concepts of 
equity that underpin the analysis and determine the primary metrics for the evaluation. Third, 
the decision problem, foundational equity concepts, and evaluation metrics determine the 
selection of an appropriate framing of choice, for example whether the analysis is used to 
describe equity impact or to explore any potential trade-off between equity and efficiency. We 
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then explore the structural and data challenges using infectious disease transmission models 
when applying economic evaluation frameworks that incorporate equity. We outline alternative 
approaches with differing degrees of integrating heterogeneity and equity into the transmission 
model structure and discuss the implications for model development, data requirements, and 
analysis. 
 
This work is supported by the International Decision Support Initiative and is intended to inform 
future guidance on the Reference Case for economic evaluation in low and middle income 
countries.  
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Introduction 
 
Worldwide, individuals experience systematic differences in their risk of acquiring, developing 
and transmitting diseases; in health outcomes when they have a disease; in their access to 
(quality) healthcare; and in the financial burden of healthcare. While the terms inequality and 
inequity are sometimes used interchangeably to describe these differences, not all inequalities 
are inequities. Health inequality is defined as “differences in health status or in the distribution 
of health determinants between different population groups” (2), whereas health inequity 
implies a judgement about the fairness or justice of systematic differences in population health 
and permits the existence of equitable inequalities and inequitable equalities.  
 
In global public health, policy makers in national governments and international donor 
organisations must make decisions about how best to allocate the resources available to them. 
Evidence from economic evaluations is increasingly influential in the priority setting process, yet 
variations in methodological approaches and reporting practices can make evidence synthesis 
challenging. The Reference Case (RC) for Economic Evaluation in Global Health (3), from the 
International Decision Support Initiative, is intended to improve the quality of this evidence base 
going forward. While economic evaluations aim to maximise the health for the resources 
available, this goal of utilitarian efficiency is not the only criteria for consideration during the 
decision making process. It is also necessary to consider the distributional effects that may arise 
from resource allocation decisions on health, healthcare utilisation and healthcare financing. This 
is reflected in Principle 11 in the RC which recommends that equity, or the fairness in the 
distribution of costs and consequences, should be considered at all stages of an economic 
evaluation. 
 
Infectious disease remain a priority in global health and mathematical models are increasingly 
being used to understand and predict the spread of infectious diseases and the impact of global 
health interventions in terms of both total gains and the distribution of gains in the population. 
Such models may be applied within an economic evaluation framework so that estimates of cost-
effectiveness include expected externality effects of interventions (4). The combination of 
transmission models with economic evaluation methods is a potentially powerful approach to 
estimate the non-linearity of intervention costs and effects over time in infectious disease.  
 
In this document, we start by reviewing the theoretical foundations of equity and the variety of 
approaches for incorporating them in economic evaluations. We then review applications in the 
published literature. Finally, we outline methodological challenges to and opportunities for 
including equity considerations in DT-EEs.  
 
  
 7 
 
Part 1: Review of equity, economic evaluations and disease 
transmission modelling 
 
Equity in health and healthcare 
Before discussing the approaches for including equity considerations in economic evaluations, 
we discuss briefly the conceptualisation of fairness in systematic differences observed in health, 
healthcare utilisation or healthcare financing. While there is no universal consensus as to what 
can be considered unfair various concepts of what fairness means and frameworks for identifying 
fair or unfair inequalities have been proposed. 
 
In the seminal paper by Whitehead, inequities are defined as something unjust or unfair and, 
importantly, something that is avoidable. Examples include health damaging behaviour where 
the degree of choice of lifestyles is severely restricted or inadequate access to essential health 
and other public services (5). Braveman and Grushkin argued against the inclusion of the 
avoidability criterion in the assessment of equity. They suggest that avoidability can be 
considered implicitly in the concepts of fairness and justice, yet fall short of defining what might 
be avoidable and the perspective to define avoidability (6). More recently Braveman and others 
have emphasised the need to define avoidability as “plausibly avoidable, i.e., at least in theory 
avoidable, based on current scientific knowledge, assuming the existence of political will”. In 
contrast, the World Health Organisation’s definition of health equity as “the absence of avoidable 
or remediable differences among groups of people” seems to emphasise avoidability as the 
principal criterion, implying that all avoidable inequalities can be considered unjust and are 
therefore inequities (7).   
 
Pereira identifies and critically appraises well-established approaches to assessing whether 
disparities in both individual and societal choices are unjust (equity foundations), namely: egality, 
distribution according to entitlement, the ‘decent minimum’, Rawlsian maximin, envy-free 
allocations, equity as choice or equality of opportunity, and equality in capabilities (Table 1) (8).  
 
Table 1: Summary of principles to define equity. 
Guiding Principle Summary 
Egality  The characteristic of interest, such as health outcome, access to healthcare 
or healthcare investment, are the same for all members of the population. 
Distribution according to 
entitlement 
Individuals are entitled to wealth providing it was acquired justly and 
therefore if they chose to spend more on their health then this remains just.  
The ‘decent minimum’ While in general distribution might be according to entitlement, there should 
be a social safety net that enables access to basic services to individuals who 
would not otherwise have the means. 
Utilitarianism The highest good is the greatest utility that can be achieved for the greatest 
number. Here, this could be linked to the concept of Pareto efficiency where 
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utilities are distributed in such a way that no one can be made better off 
without making someone else worse off. 
Rawlsian maximin Maximising benefits to the least well off. Unlike the decent minimum, the 
maximin principle would continually strive to improve welfare for the least 
advantaged, independently of the overall distribution of benefits and 
independently from whether overall inequality is increasing.  
Envy-free allocations Here it is acknowledged that just inequalities may arise from differences in 
individual preferences. Therefore, an optimal distribution is one in which 
individuals do not envy the health or healthcare available to others. 
Equity as choice People should be allowed to make individual decisions from equal choice 
sets. 
Equality in capabilities Capability theory recognises the importance of individual agency (departing 
from outcome focus principles such as egalitarianism) but notes that in order 
for individuals to be able to make truly comparable choices they must have 
equality in basic capabilities. Here, health could be seen either as an 
outcome dependent on the choices of individuals, or as a component of 
basic capabilities necessary to make free and fair choices.  
Source: Principles adapted from Pereira (8) 
 
Preferences for competing conceptions of equity are driven in part by ideology (9), underpinning 
the interpretation of inequalities (which are value-free) to inequities (which are include a value 
judgement). Whether differences in health, access to healthcare or healthcare financing are fair 
or not may depend on beliefs about the extent to which individuals are themselves responsible 
for ensuring their own outcomes and access to healthcare. There is a gradient in attitudes 
towards individual vs collective responsibility, with neoliberal or libertarian ideologies 
emphasising individual responsibility, for example ‘distribution according to entitlement’ and 
‘decent minimim’, and socialist or communitarian ideologies emphasising collective 
responsibility and a role for government or communities to ensure a more equal health access 
or outcomes, for example the principles of equality or equality in basic capabilities. Rawlsian 
maximin perhaps sits more towards the middle, being both focused on improving outcomes for 
the least advantaged while permitting the better off to maintain or even increase their relative 
advantage.  
 
In conclusion, Pereira identifies Sen’s framework for conceptualising social value not in terms of 
material goods and services or even individual utility, but rather as the capabilities human beings 
require to flourish, as the most promising approach, as it focus equity concepts on individual 
freedom and agency (equality-in-basic-capabilities) (8). Despite efforts by several groups (10,11), 
capabilities have not been widely taken up as a quantitative outcome metric and health-related 
outcomes remain dominant in intervention evaluations.  
 
However, health can itself be thought of as a capability rather than utility. That is, individuals do 
not derive utility directly from good health, but by deriving utility from life, supported by the 
capability of good health. This could be considered to support the World Health Organisation’s 
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definition of health equity as “the absence of avoidable or remediable differences among groups 
of people” (7). Here the goal is not an egalitarian distribution of capabilities required to achieve 
good health but the equalisation of health itself, wherever possible. In effect, this definition 
retains only the avoidability criterion from Whitehead’s definition of health equity. Reversing the 
original argument of Braveman and Gruskin, fairness is subject to the concept of avoidability; if 
health is a capability then health inequalities that are avoidable are therefore unfair. This view 
has resonance in the idea of health as a fundamental human right. 
 
At this point, depending on the defining approach to equity considered, a key question then 
becomes whether it is the distribution of health outcomes, healthcare access or resources 
(healthcare financing) that should be considered. In a recent report, Braveman and others 
describe health equity as follows: “health equity means that everyone has a fair and just 
opportunity to be healthier. This requires removing obstacles to health such as poverty, 
discrimination, and their consequences, including powerlessness and lack of access to good jobs 
with fair pay, quality education and housing, safe environments, and health care”. In other words, 
access to healthcare services is not sufficient, other capabilities should also be supported but, if 
these are in place, then resulting inequalities in health outcomes or healthcare utilisation (due to 
individual agency) are not considered inequities. Moreover, more or better health is not the only 
potential benefit of healthcare or public health investment, for example reduced risk of illness 
may also reduce the risk of catastrophic out-of-pocket expenditure (12). Culyer takes the view 
that equality of health itself should be the dominant principle, and that healthcare should 
distributed in order to achieve as close to an equal distribution of health as is feasible (13,14). 
The difference between equality in the distribution of resources and the distribution of outcomes 
can be considered in terms of “horizontal” and “vertical” equity. According to Culyer, “horizontal 
equity requires the like treatment of like individuals and vertical equity requires the unlike 
treatment of unlike individuals” (15). That is, horizontal equity is provision of similar services for 
people with similar health needs while vertical equity preferentially provides services to less 
advantaged populations. Both could be seen as fair, yet provide different recommendations on 
how to act. 
 
Equity considerations in economic evaluation 
Healthcare economic evaluation is the assessment of alternative courses of action by comparing 
their costs and consequences. In standard application of most common economic evaluation 
frameworks such as cost-effectiveness analysis (CEA) and cost-benefit analysis (CBA), the aim is 
to maximise benefits given the resources. While the focus is on efficiency, distributional 
considerations of alternative courses of action should be also addressed in the decision process 
and so the importance of the conceptualisation of equity lies in determining whether and how to 
incorporate it into the decision-making and resource allocation processes. In this section, we 
consider current approaches for the incorporation of equity within economic evaluation. 
 
In examining these approaches, it is useful to consider the theoretical foundations of economic 
evaluation. As outlined by Brouwer and others, welfarism and extra-welfarism constitute 
competing epistemological perspectives upon which health economists develop frameworks for 
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applied economic evaluation (16,17). Welfarism considers the social welfare of a given action to 
be the sum of the utility gained (or lost) by each individual in the population affected. In this 
respect, it is an essentially utilitarian framework, seeking the greatest total utility, distribution of 
gains or losses felt by the population. Extra-welfarism, as the name suggests, seeks to introduce 
additional characteristics to the welfarist position. These additions have not been codified 
succinctly or consistently. While acknowledging the various versions of extra-welfarism, the 
authors go on to suggest that two issues lie at the centre of the differences between the schools 
of thought: 1) The source and nature of valuation; and 2) The initial distribution of wealth and 
income and Pareto principle applied to the final state. The implications of these differences in 
applied economic evaluation are summarised in Table 2. 
 
Because equity relates to both issues (valuation and distribution), it is, for many, an example of 
an “extra” consideration to a standard welfarist view and is therefore an example of an extra-
welfarist issue. With respect to the valuation of outcomes, consideration of equity implies that 
we value not only individual welfare but also the distribution of welfare in a population.  
 
Table 2: Summary of welfarism and extra-welfarism (from Brouwer 2008) 
 
Under welfarist economics Under extra-welfarism 
Relevant 
outcomes 
Only individual utility, normally taken 
to represent preference orderings. 
Social welfare is a function of 
individual welfares 
May include individual utility as well as extra measures 
and indicators of well-being. In health policy, common 
outcomes will include health or health gain and the 
distribution of health or health gain, but may include 
other measures like patient satisfaction or caregiver 
burden. The selection of relevant outcomes is an 
important element in extra-welfarist evaluation and is 
context dependent and seems not for economists to 
decide (rather for decision-makers with authority). 
Some outcome measures may be based on preference 
measurement, when this is deemed a useful way to 
measure characteristics of interest 
Valuation of 
relevant 
outcomes 
As a rule the affected individual Might be the affected individual, but could also be an 
expert or a representative sample of the general public 
or an authoritative decision-maker 
Weighting of 
relevant 
outcomes 
Sometimes permitted in a social 
welfare function, where the weights 
normally pertain to the distribution 
of individual utilities. Unclear 
whether such weights still classify as 
utility information 
Allowed and often considered important as means of 
incorporating equity and other considerations. Weights 
may be based upon a variety of ethical considerations 
including wealth, need and desert and can relate to the 
variety of relevant outcomes considered important (e.g. 
capabilities) 
Interpersonal 
comparability of 
Although some theoretical 
approaches allow it (e.g. in a social 
welfare function), especially in 
applied work, normally considered 
Explicitly allowed in the relevant outcomes, though 
normally not in terms of individual utility, but rather in 
terms of capabilities and characteristics like health, 
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Approaches to equity analysis in economic evaluation  
Recent efforts to improve quality and comparability of economic evaluations across settings led 
the International Decision Support Initiative to develop a RC for economic evaluation in global 
health (3). The RC included equity considerations as one of 11 core principles for economic 
evaluation, noting that: 
“There are various methods available for assessing equity implications of an intervention: 
• The method chosen should be appropriate to the decision problem and justifiable to the decision 
maker 
• Equity implications should be considered at all stages of the evaluation, including design, analysis 
and reporting” 
In a 2012 systematic review, Johri and Norheim identify three broad approaches to 
incorporating equity considerations into economic evaluations: i) Equity weights and social 
welfare functions, ii) Multi-Criteria Decision Analysis (MCDA), and iii) Mathematical 
programming (18). Furthermore, a recent review by Cookson and others introduces the concept 
of the health equity impact plane, drawing attention to two frameworks to incorporate equity 
considerations into CEA: Distributional Cost-Effectiveness Analysis (DCEA) and Extended Cost 
Effectiveness Analysis (ECEA) (described further below). Cookson and others also highlight the 
distinction between equity impact analysis and equity trade-off analysis. Equity trade-off 
analysis will only be necessary if the equity impact analysis identifies a potential trade-off 
between efficiency and equity (quadrants II and IV on the equity impact plane). 
Building on these reviews, we identified approaches to incorporating equity considerations into 
economic evaluations through non-systematic database searches supplemented reference 
screening and categorised frameworks into the following groups: 
a) Methods that allow for equity weighting (multiple cost effectiveness thresholds, HAI, MAES, 
fairness in CBA) 
b) Methods that allow for equity to be included as an additional evaluative criteria (MCDA, ECEA) 
c) Methods that quantify trade-offs in equity against efficiency (DCEA, MP) 
d) Methods that allow the simultaneous qualitative consideration of equity and efficiency 
(checklists and embedding frameworks, descriptive analyses) 
Below and in Table 3 we review and summarise these approaches by categories. 
 
Methods that allow for equity weighting  
A foundational assumption in standard cost-effectiveness or cost-utility analyses is that the value 
of health gains is identical for all individuals, often described in the refrain “a QALY is a QALY is a 
QALY”. In 2009 Wailoo and others argued that economic evaluation methods were not yet ready 
for applied equity adjustments to health utility scores (19). However, in the years since, methods 
for equity weighting have continued to develop and are becoming increasingly popular (20,21). 
Equity weighting allows the analyst to quantify the relative importance of the relevant equity 
concepts. Several frameworks for equity weighting of outcomes are described below.  
relevant 
outcomes 
impossible in the relevant evaluative 
space, i.e. individual utilities 
handicap, ability to cope, schooling, ability to exercise 
discretion 
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Multiple Cost Effectiveness Thresholds 
Differential valuation of health outcomes using separate cost effectiveness thresholds is perhaps 
the most direct approach to equity adjustment of health outcomes. An example is the decision 
of the National Institute for Health and Care Excellence (NICE, then National Institute for Health 
and Clinical Excellence) for England and Wales, to apply a higher cost-effectiveness threshold for 
end of life care (22), though empirical research into people’s acceptance of this differential 
valuation did not find support and the policy has been criticised by some1 (23).  
 
Health Achievement Index 
Wagstaff’s Health Achievement Index (HAI) integrates the average level of health in a population 
and the inequality in health between the poor and the better-off (24). Ngalesoni and others use 
HAI to appraise the distribution of outcomes in an economic evaluation of cardiovascular 
prevention in Tanzania (25). The study is notable as an example of equity economic evaluation in 
an LMIC. 
 
Multi attribute equity state 
Round and Paulden describe a framework for using a multi attribute equity state (MAES) within 
CEA. Here, different health outcome valuations are incorporated into a single equity state metric. 
In contrast, to HAI, MAES weighting might reflect empirically measured societal values for 
differential weighting of outcomes in specific context, such as end-of-life care (21).  
 
Fairness in CBA 
Samson and others adapt the cost-benefit framework, whereby health outcomes are converted 
to monetary value, using an equity adjusted rate of equivalent income. Unlike some other 
economic evaluation frameworks, the use of CBA as a basis of equity analysis allows the inclusion 
of non-health outcomes.  
 
Methods that allow for equity to be included as an additional evaluative criteria  
In contrast to equity weighting, where different valuations on health are incorporated into a 
single measure, other frameworks include equity, or equity-related measures, as an additional 
criteria that is separate from the quantification of expected health gains.  
 
Multi Criteria Decision Analysis 
Baltussen and others argue that the plurality of evaluative frameworks to inform priority setting 
highlights the need for an approach to quantitatively compare alternative courses of action using 
multiple criteria. Multi Criteria Decision Analysis (MCDA) allows analysts to combine costs, 
effects, equity and other considerations through a systematic quantitative weighting of the value 
of each criterion by decision makers. While MCDA has more commonly been applied in high 
income countries it has also been applied in some low and middle income countries (30).  
 
                                                             
1 The criticism centres on the argument that QALYs  at the end of life are not inherently more valuable and 
permitting expenditure on interventions which are therefore less cost-effective has an opportunity cost, 
preventing the provision of more beneficial services.  
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Extended Cost Effectiveness Analysis 
As part of the Disease Control Priorities project, Verguet and others have proposed Extended 
Cost Effectiveness Analysis (ECEA), a framework for incorporating financial protection impact as 
well as health outcomes in economic evaluation (31). ECEA presents the expected impacts of an 
intervention on financial protection, for example averted catastrophic out-of-pocket health 
expenditure or averted cases of poverty, in addition to and alongside health outcomes. This is 
particularly relevant in LMICs where the cost of healthcare can require the sale of assets and 
property among poor populations, threatening livelihoods (32). Unlike MCDA or equity-weighting 
approaches, outcomes in ECEA are not aggregated into a single result.  
 
Methods that quantify trade-offs in equity against efficiency 
Distributional cost-effectiveness analysis 
Asaria and others describe a framework for Distributional Cost-Effectiveness Analysis (DCEA). 
This framework has two stages: 1) modelling of the changes to baseline health distribution due 
to the intervention and adjust them for social value judgements of fairness; and 2) quantification 
of changes in total population health if all unfair differences in are removed and evaluation of 
trade-offs between improving population health and reducing unfair health inequality. DCEA also 
emphasises the importance of the distribution of opportunity costs in the population, since 
alternative spending to an intervention of interest could also be expected to affect the 
distribution of health outcomes (33,34). 
 
Mathematical Programming 
The Mathematical Programming approach (or constrained optimisation) typically frames a 
decision problem in terms of a desirable outcome to be maximised (the objective function) and 
a set of one or more constraints limiting maximisation. In this framework, various equity 
conditions may be included as a constraint to the maximisation of health. For example, Cleary 
and others examine HIV treatment in South Africa and constrain the objective function by both 
cost and various social welfare considerations including equal treatment, a decent minimum and 
health maximisation (35). It is also possible to include equity in the objective function alongside 
health maximisation as Verguet does in an analysis of HIV prevention also in South Africa (36). In 
both approaches, any trade-off between health maximisation and equity constraints or 
maximisation can be presented as scenario analysis.  
 
A drawback of a Mathematical Programming approach is that the decision problem is typically 
more locally constrained than CEA. The use of a cost effectiveness threshold in CEA reflects (in 
theory) the opportunity cost of alternative marginal investment in the health sector and 
therefore widespread and quality application of CEA supports efficient health sector planning. In 
contrast, Mathematical Programming considers the opportunity cost of direct alternatives 
available to the model.  
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Methods that allow the simultaneous qualitative consideration of equity and efficiency 
Checklists and embedding frameworks 
In addition to the frameworks for quantitatively incorporating equity considerations into 
economic evaluation described above, several supporting checklists have been proposed. Culyer 
and Bombard (50) offer a framework to guide and appraise health technology assessments. As 
part of a WHO initiative on health equity, Norheim and others propose to embed the 
consideration of cost-effectiveness analysis evidence in a framework they call Guidance for 
Priority Setting in Healthcare or GPS-Health. The framework aims to be a comprehensive checklist 
to support decision makers in the consideration of equity issues potentially missing from cost-
effectiveness evidence (37). Daniels and others emphasise a transparent deliberative process for 
decision makers to consider Health Technology Assessment (HTA) evidence, they call 
“Accountability for Reasonableness (A4R) (38,39). 
 
Descriptive analysis and qualitative comparison 
It is relevant to mention methods for descriptive analysis of health-related equity that do not 
attempt to compare costs and consequences and are therefore not economic evaluation 
methods but can help inform the decision making process. On the simplest level, economic 
evaluation may be applied to two alternative courses of action where one is considered more 
equitable than another (depending on the conceptions of equity outlined in the previous 
section). The costs and consequences of each course of action are assessed and if the superior 
option in terms of equity is also more efficient (cost-effective) then this choice dominates. If the 
superior choice in terms of equity is less efficient then a qualitative judgement must be made as 
to whether the difference in efficiency outweighs the difference in equity.  
 
Further analysis may support a quantitative understanding of intervention equity and therefore 
compliment the quantitative analysis of cost-effectiveness. Benefit incidence analysis evaluates 
the distribution of health impacts in a population while financing incidence analysis and resource 
allocation comparisons respectively appraise from which population groups funds are raised and 
to whom they are distributed (40–42). Such analysis is potentially complementary to economic 
evaluation, though as Cookson and others point out, unlike economic evaluation theses analyses 
tend to consider average rather than marginal effects (43), with some exceptions (44).
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Table 3: Summary of equity frameworks relevant for healthcare economic evaluation. 
Thematic 
Approach 
Framework Brief Description Interaction with Transmission 
Models 
Outcome Metric Selected 
References 
Equity weights 
and social 
welfare 
functions 
Multi-attribute 
equity state 
Quantitative inclusion of equity into 
health outcome measurement through 
equity weighting on multiple dimensions. 
The application of differential 
weights to transmission model 
outcomes is straight forward and 
analogous to the weighting of 
outcomes from other health 
economic models.  
Health Utility Round and 
Paulden (21) 
 Health 
Achievement 
Index (HAI) 
Combines the distribution of health with 
the mean for an aggregate measure of 
efficiency and equality for a given 
inequality aversion parameter. 
As above Health Utility Wagstaff (24) 
 Multiple cost-
effectiveness 
thresholds 
Using different thresholds for different 
populations is equivalent to applying 
weights to health utility scores, both are 
an adjustment to the value of health for 
different populations. 
As above Health Utility (22,23,45) 
 Cost-based equity 
weight 
Weights costs rather than outcome 
measures. 
As above Any Ong et al. (46) 
 CBA with social 
welfare function – 
equivalent income 
Defines welfare loss in terms of 
“equivalent income” i.e. richer 
individuals may have a lower equivalent 
income than poor individuals if they are 
in poor health. Different preferences in 
health are allowed. Aggregation of net 
benefit factors in distribution of 
equivalent income through a social 
welfare function. However, valuation of 
There is the potential to use 
individual WTP with individual 
based models for this framework. 
However, there would be a 
complication with individual-based 
transmission models due to the 
externality effects. That is, an 
individual may value not only their 
own gains but also gains for others.  
Monetary 
Equivalent 
Samson et al 
(47) 
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health remains dependent on income, 
raising ethical objections. 
Additional 
Criteria 
Extended Cost 
Effectiveness 
Analysis (ECEA) 
Inclusion of an assessment of financial 
protection outcomes in addition to 
health outcomes. 
In addition to straightforward post-
simulation accounting of health 
effects, costs and financial 
protection, it would be possible to 
link healthcare seeking decisions to 
ability-to-pay, therefore assessing 
impact of financial protection on 
indirect health effects.   
Health Utility 
and Financial 
Protection 
Verguet and 
others 
(31,48,49) 
 Multi Criteria 
Decision Analysis 
(MCDA) 
MCDA sees costs and effects as only two 
out many potential criteria that would 
inform a policy decision.  The framework 
seeks to quantify and weigh all relevant 
criteria to inform a decision.  
MCDA would simply embed any 
transmission modelling analysis 
and allow quantitative 
consideration of factors not 
included in the model. 
Health Utility or 
disease specific 
measures in 
addition to non-
health outcomes 
Baltussen and 
others (26–30) 
 Cost-Consequence 
Analysis (CCA) 
CCA allows the reporting of non-
quantified costs or consequences in 
addition to quantified results in a tabular 
balance-sheet format. 
As above As above (50) 
Equity-
Efficiency 
Trade-off 
focused 
Analyses 
Mathematical 
programming 
Mathematical programming is a term 
referring to the use of mathematical 
models to address health economic 
questions (constrained optimisation) but 
does not include disease transmission 
modelling.  
Algorithmic resource allocation 
using constrained optimisation 
rather than CEA decision rules 
Health utility, 
disease-specific 
measures or 
goal-oriented 
optimisation 
Examples: 
Stinnett and 
others (51);  
Cleary and 
others (35) 
 Distributional Cost 
Effectiveness 
Analysis (DCEA) 
Quantitative assessment of equity 
impact and potential trade-offs between 
efficiency and equity through fairness-
adjusted health estimation. 
Unlike some equity economic 
evaluation equity frameworks, 
DCEA emphasizes the simultaneous 
assessment of multiple dimensions 
of equity. Integrating several 
dimensions of heterogeneity into a 
Health Utility Asaria, 
Cookson and 
others (33,34) 
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dynamic transmission model may 
be challenging. 
Embedding 
Frameworks 
and 
Descriptive 
Analysis 
Resource 
allocation 
comparison 
Financing 
incidence analysis 
Benefit incidence 
analysis 
Descriptive analysis of the population 
distribution of resources, health gains 
and /or financial burden of an 
intervention. 
These approaches do not attempt 
quantitative integration with 
economic evaluation and therefore 
can be applied in the same way to 
dynamic transmission economic 
evaluations. 
- Various (40–
42,52–54) 
 Guidance on 
Priority setting in 
Healthcare (GPS-
Health) 
A checklist of equity criteria that are 
relevant to health care priority setting 
and may be considered in addition to 
cost-effectiveness analysis. 
As above - Norheim et al 
(37) 
 Checklist As above As above - Culyer and 
Bombard (55) 
 Accountability for 
Reasonableness 
(A4R) 
Embed HTA in a “fair, deliberative 
process”. 
As above - Daniels et al 
(38,39) 
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A cross-sectional literature review of equity in economic evaluations 
It is widely acknowledged that equity is an important consideration in health policy, and 
discussions of whether, and how, to include it in healthcare economic evaluation can be traced 
back to the origins of the disciplines. However, equity does not commonly feature in such 
analyses. A review of HTA agency practices between 2006 and 2011 found that consideration of 
health equity was not standard practice (56). Furthermore, Johri and Norheim identified only 51 
economic evaluations that included equity from a search of the Pub Med and EMBASE databases 
between 1996 and 2008 (18).  
 
To assess the extent to which equity is considered in economic evaluations, we make use of an 
existing resource: Pitt and others undertook a comprehensive search of multiple databases and 
grey literature sources to identify 2844 economic evaluations published between January 2012 
and May 2014 (57). We searched titles and abstracts of studies in this dataset for the key words; 
equity, inequity, inequality, distributional, fairness or justice. The criteria for inclusion were i) 
that the study is an applied economic evaluation and ii) includes quantitative consideration of 
equity for any sub-population grouping. The evaluation framework, outcome measure and 
outcome model type were extracted for each study. 
 
The search returned 33 results from 2844 records. Of these, eight met the inclusion criteria (Table 
4), approximately 1 in 355 studies. Most studies used a cost-effectiveness or cost-utility analysis 
framework or similar (n=7) with a descriptive analysis of equity considerations, with one study 
using a constrained optimisation or mathematical programming approach (36). One study 
applied cost-benefit analysis alongside CEA (58). Two studies used DALYs as the outcome 
measure (59,60) and one uses QALYs (61) with the remaining using versions of ‘natural’ outcome 
units for the relevant context. Only one study used a dynamic Markov simulation to estimate 
health outcomes (61) and there were no studies that included dynamic simulation of disease 
transmission. 
 
Consideration of equity in applied economic evaluations is thus rare and mainly descriptive. 
When equity is considered, simple disaggregation of results and scenario analysis of alternative 
more or less equitable courses of action is the most common approach. Methodological 
approaches to quantitatively assess equity impact and equity trade-offs were not found to be 
applied in these studies.
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Table 4: Economic evaluation that include analysis of health equity (2012-14) 
Year First Author Title Framework Outcome Outcome model Equity Approach Journal Source 
2014 Blakely T Cost-effectiveness and equity 
impacts of three HPV 
vaccination programmes for 
school-aged girls in New Zealand 
CEA/CUA QALYs Dynamic 
compartmental 
(Markov) without 
dynamic 
transmission 
Descriptive analysis 
and qualitative 
comparison 
Vaccine (61) 
2012 Hounton S Applying the Net-Benefit 
Framework for Analysing and 
Presenting Cost-Effectiveness 
Analysis of a Maternal and 
Newborn Health Intervention 
CEA & CBA Institutional 
delivery & 
monetary 
equivalent 
Empirical & OLS 
regression 
Descriptive analysis 
and qualitative 
comparison. 
Including regression 
analysis of 
determinants of 
cost-effectiveness 
PLOS ONE (58) 
2012 Waters D Optimizing community case 
management strategies to 
achieve equitable reduction of 
childhood pneumonia mortality: 
an application of Equitable 
Impact Sensitive Tool (EQUIST) 
in five low- and middle-income 
countries 
CEA/EQUIST Lives Saved Static deterministic Descriptive analysis 
and qualitative 
comparison 
Journal of 
Global Health 
(62) 
2012 Rheingans R Distributional impact of 
rotavirus vaccination in 25 GAVI 
countries: Estimating disparities 
in benefits and cost-
effectiveness 
CEA/CUA DALYs Static deterministic Descriptive analysis 
and qualitative 
comparison 
Vaccine (59) 
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2012 Cobiac L Cost-effectiveness of extending 
the coverage of water supply 
fluoridation for the prevention 
of dental caries in Australia. 
CEA/CUA DALYs Static deterministic Descriptive analysis 
and qualitative 
comparison* 
Community 
Dentistry and 
Oral 
Epidemiology 
(60) 
2013 Baker J Ethnic differences in the cost-
effectiveness of targeted and 
mass screening for high 
cardiovascular risk in the UK: 
cross-sectional study 
CEA High-risk 
person 
detected 
Static deterministic Descriptive analysis 
and qualitative 
comparison ** 
Heart (63) 
2013 Verguet S Efficient and equitable HIV 
prevention: a case study of male 
circumcision in South Africa. 
Constrained 
optimisation 
- Static deterministic Equity-Efficiency 
Trade-Off Analysis 
Comparison of 
efficient and 
egalitarian 
optimisation 
constraints 
Cost 
Effectiveness 
and Resource 
Allocation 
(36) 
2012 Carrera A The comparative cost-
effectiveness of an equity-
focused approach to child 
survival, health, and nutrition: a 
modelling approach. 
CEA-like 
(outcome per 
expenditure) 
Under 5 
mortality 
Static deterministic Descriptive analysis 
and qualitative 
comparison 
Lancet (64) 
* Cobiac and others argue for the intervention in smaller communities despite conducting a regular CEA and finding that the marginal extra rollout is not cost 
effective. ** Baker and others make a qualitative inference about equity impact but do not model this. 
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Part 2: Key Methodological Considerations 
 
In this section, we discuss the key methodological considerations when including equity in 
economic evaluations using transmission models. For each consideration, we state the 
problem, and define the methodological steps needed to be taken by the analyst.  
 
Defining the policy question 
The purpose of economic evaluation is to support decision making, so at the beginning of any 
analysis, it is important to define the policy question. When doing so, analysts will need to 
consider the equity concept of interest and the perspective of the decision maker.  
 
Perspective 
In global health, there are global payers in addition to domestic payers. In the same way that 
different payers will have different cost-effectiveness decision rules, in equity-informed 
economic evaluations, one can expect different perspectives in the value judgement needed to 
define the equity question. Currently, there are various methods and processes to support 
decision makers and analysts who support them in including equity-relevant considerations in 
the decision-making process. Decision makers could be interested in including equity 
(quantitatively or qualitatively) as an additional evaluative criteria (26,31,37,55), quantify trade-
offs between equity and efficiency (34,51), or weighting cost-effectiveness results on equity 
measures (21,22,24,47). We do not elaborate on these various methods and processes in this 
report. We have reviewed them in the previous equity review that will be made available before 
the workshop. During the workshop, we will aim to discuss whether more extensive guidance is 
needed. However, central to the methodological steps to perform an equity-informative 
economic evaluation and developed further will be the type of equity that concerns decision 
makers. 
 
Equity concepts 
The difference between inequalities (heterogeneity between population groups) and inequities 
is a value judgement about whether the observed inequality is fair or just. There are a range of 
philosophical frameworks that underpin the inequities (summarised in Table 1).  A choice 
between these equity-defining principles will frame the analysis in terms of choices in metrics, 
evaluative frameworks, model structure, and analysis plan.  
 
Sub-groups of interest 
The conceptual principles informing the characterisation of equity in economic analysis might not 
always be explicitly defined (9). Policy makers may be concerned with prioritisation of gains 
within a pre-specified vulnerable population group or achieving more equal distribution of 
benefits, without prior specification of a population group of interest. For example, Verguet et 
al. consider the trade-off between efficiency (maximising HIV infections averted) and equity 
(geographical equity in access to services) of alternative programmes for male circumcision as 
 22 
 
HIV prevention among men in South Africa (2). In this case, we approach the policy question 
aiming to evaluate equity from the perspective of access to care for men, specifically. 
Alternatively, the decision maker may have no pre-specified equity goal but nevertheless be keen 
to consider the impact of a particular course of action on the distribution of benefits as well as 
total gains (65). 
 
Choice of evaluation framework 
After defining the equity problem broadly, the analyst will need to choose an evaluation 
framework for analysis. In making this choice, considerations should be given to the outcome of 
interest and the analytical approach. 
 
Outcome of interest 
Decision-makers may be interested in equity considerations in health, access to healthcare, 
healthcare financing, financial protection, well-being including non-health factors, or capabilities. 
A choice to focus on health financing or access rather than health itself, for example, would fall 
out of a concept of equity, such as equality in capabilities, that places the onus on the provision 
on access or means to ensure access to healthcare to individuals, but does not accept policy 
responsibility for ensuring their health outcomes.  
 
Analytical approach 
In economic evaluation, the choice of outcome also defines the choice of economic evaluation 
analytical approach to assess efficiency. For example, expressing outcomes in monetary terms 
implies a cost-benefit analysis (CBA) while disease-specific measures imply cost-effectiveness 
analysis (CEA).  
 
The selection of analytical approaches for equity considerations in economic evaluations will also 
be informed by the choice of primary metric of interest, among others. There are several 
analytical approaches in economic evaluation that have clear ideological foundations with 
respect to equity. Unlike CEA or cost utility analysis (CUA), CBA converts all costs and 
consequences to monetary units and presents results in terms of the aggregated Net Benefit 
(benefits minus costs), by valuing health using an individual’s willingness-to-pay (WTP) for 
expected health gains. The notion that it is individual decisions that reflect rational self-interest 
that should be used to value health implicitly accepts inequalities in ability-to-pay and therefore 
aligns with a “distribution according to entitlement” ideology of health-related equity (see 
previous report). That is, what matters is the value an individual places on health given the 
resources at their disposal. While a population average WTP is often used, as Robinson and 
Hammitt note, in terms of the CBA normative framework for valuing health this over-weights the 
preferences of poorer individuals and under-weights the preferences of the wealthy (66). The 
incorporation of a social welfare function2 into CBA allows the analysis to shift the framework 
from a “distribution according to entitlement” ideology to a more pro-poor or egalitarian 
approach by differentially weighting gains according to the sub-groups within which they accrue. 
                                                             
2 A function to value social states as more or less desirable.  
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Again, it may be important to be transparent and explicit about shifts in foundational equity 
concepts as equity economic evaluation is increasingly applied.  
 
Second, ECEA includes impact on financial protection, or the avoidance of catastrophic 
expenditure due to out-of-pocket payments, alongside costs and health effects. The concept of 
catastrophic expenditure requires a threshold to be applied to determine which out-of-pocket 
payments should be considered catastrophic. In equity terms, this threshold approach recalls a 
“decent minimum” equity standard, whereby there is collective responsibility to ensure certain 
minimum standards are applicable to all or a Rawlsian focus on improving outcomes for the least 
advantaged without consideration of the overall distribution of benefits.  
 
Finally, Cookson et al. separate equity economic evaluations into two distinct groups i) equity 
impact analysis and ii) analysis of potential equity-efficiency trade-offs (67). Equity impact 
analysis is descriptive and provides information on the distribution of costs and consequences 
while trade-off analysis considers the extent to which aggregate health gains are reduced, if at 
Box1: Increasing vaccine coverage 
What is the problem? To illustrate the impact of inclusion of transmission effects on alternatives tested and 
conclusions  
What do we know already? Investments to increase coverage across a population will be faced with a 
differential uptake across subpopulations. Additional targeted resources to increase coverage in those harder-
to-reach is potentially not cost-effective when judged on mean effects. But if those harder-to-reach are 
poorer or rural populations, then this prioritisation could be considered equitable. Example: Distributional 
cost-effectiveness analysis in low-and middle-income countries: illustrative example of rotavirus vaccination 
in Ethiopia (39).  
What will this illustration add? The added value of transmission modelling as a frame for the analysis will be 
two-fold:  
1) Provides the opportunity to test additional equity-relevant policy options, for example: additional 
targeted resources to increase coverage in the remainder of the population (easy-to-reach group). 
The change in analysis frame allows us to examine direct and indirect impacts so that targeting easy-
to-reach groups may result in both a reduction of inequities and a cost-effective alternative. 
2) Presents challenges in acceptability of recommendations and the communication of results as it may 
not be acceptable for policy makers to be seen as prioritising population groups already at an 
advantage, even though this course of action could be considered more cost effective and produce 
equitable outcomes. 
What would be the relevant message for the following stakeholders?  
1) national and regional governments/payers: challenges of interpreting results for within country 
decisions when equity concerns are being explicitly stated. 
2) global donors/development partners: help frame equity and political considerations at country level 
that might influence countries priority setting in applications for funding. 
3) researchers in LMICS and HICs: key methods considerations on how to frame the equity question and 
the results that could be discussed using this example. 
4) iDSI : illustration of the added value of transmission models when applying the reference case to 
economic evaluations. 
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all, by interventions intended to improve equity in some way compared to those simply seeking 
to maximise total (i.e. average) health. In both equity impact analysis and equity trade-off 
analysis, judgements about the fairness of results are, to some extent, exogenous to the analysis. 
As descriptive analysis, equity economic evaluation frameworks employed for equity impact 
analysis may employ various approaches to quantitatively or qualitatively appraise the 
distribution of costs and consequences. The interpretation of these results may be left to the 
reader or included in the discussion of the results in the paper but the value-judgement is unlikely 
to be contained in the analysis.  
 
In equity trade-off analyses, like DCEA (34), alternative scenarios that are compared and the 
analysis focus on the trade-offs between maximising efficiency or equity. Are we willing to accept 
a loss in total health gains for a pro-poor screening programme that improves outcomes for those 
in the lowest income group? A more extreme question (which we believe will not be uncommon 
as this approach develops) is to what extent are we willing to accept negative health gains in a 
subpopulation even if the total (i.e. average) health gains are positive. In some cases, the value-
judgement of the trade-off may be left to the reader, however, value-judgements, sometimes 
implicit, may have shaped the characterisation of the “equity” scenario in a comparison of equity-
efficiency trade-offs. For example, this may take the form of assuming greater equality of 
outcomes is desired between a marginalised group and the rest of the population. To what extent 
do we value improving outcomes among this disadvantaged group compared with simply 
improving health in the population as a whole? Again, this will be framed in general terms by the 
equity perspective guiding the analysis. 
 
Structure  
Heterogeneity dimensions 
Transmission models sit within the standard economic evaluation frameworks in broadly the 
same way as  non-transmission models. That is all produce average estimates of costs and effects 
for an intervention for a defined population over a defined time period, and the economic 
evaluation framework uses the model outputs to generate summary measures of efficiency. A 
key methodological challenge, when considering the integration of equity considerations into the 
economic evaluation frame, is the decision around whether to (and how to) incorporate equity-
related dimensions of heterogeneity (equity heterogeneity) into the evaluation, in addition to 
risk-related dimensions (risk heterogeneity) already part of the transmission model structure. 
This poses a range of questions relating to model structure and data requirements.  
 
To illustrate the potential implications of equity analysis for model structure and data, let us 
consider the role of financial protection on individual behaviour such as treatment seeking. In 
this case, a programme to reduce user fees may both reduce catastrophic expenditures and, 
because of this, increase uptake and timeliness of treatment, further reducing transmission, 
particularly among those at risk of impoverishment through ill health, who in turn are at an 
increased risk of infection. The heterogeneity that drives the distribution of each of the aspects 
of the impact on user fees, uptake, risk and infection may be different. 
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In transmission modelling, the principal reason for inclusion of heterogeneity is to capture 
variation in risk of infection (and/or disease), without value judgement – our risk dimension. For 
example, behavioural risk factors, such as occupation, sexual activity and migration, or contextual 
risk factors such ecological suitability for disease vectors, density of urban living spaces or access 
to quality healthcare. Equity analysis adds a further consideration to the structural decisions of a 
transmission model, in that the equity heterogeneity should also be linked to the definition of 
subgroups by characteristics where differences in outcomes will be considered unjust, such as 
differences in access to care between groupings by ethnicity or differences in health outcomes 
by socio-economic status.  
 
Certain dimensions of heterogeneity are commonly found in both equity analysis and 
transmission modelling, for example, age and gender. More generally, a key concern when 
deciding the population groups to distinguish in the model is to assess whether equity and risk 
dimensions are correlated or not. In some cases, data available for analysis of heterogeneities 
may occur at a level of population aggregation rather than at individual level. For example, 
geography, usually in terms of administrative boundaries such as provinces districts or villages, is 
a natural way to define population sub-groups and can be used consider heterogeneity in some 
characteristics. Care should be taken as aggregation may in some cases mask heterogeneity 
observable at higher resolution.  
 
After the relevant heterogeneity (equity and risk) dimensions are defined, an important 
structural consideration will be the extent to which equity heterogeneity is integrated into the 
transmission model structure or treated separately. To unpack these structural challenges, we 
consider a number of general approaches from simplest to most complex, below.  
 
Cases distributed through equity dimension(s) post-simulation 
Let us consider a transmission model that is homogenous with respect to the equity dimension(s) 
of interest. This transmission model is still useful with respect to an economic evaluation in that 
it estimates the indirect effects of reduced transmission; however assumptions must be made 
about the distribution of all effects (direct and indirect) with respect to equity related 
heterogeneity.  
 
Figure 1: Simple post-simulation inclusion of equity-related heterogeneity 
 
 
 
For example, if a pre-existing transmission model of influenza vaccination estimates a 60% 
decline in cases for the whole population, while in contrast, an impact calculation considering 
the direct protective effect of those who receive the vaccine might estimate a 40% reduction. 
 26 
 
Any equity analysis that previously may have used the “static” impact calculation may instead 
use the transmission model outputs and improve on this average estimate. That is, the added 
benefit in using a transmission model is a more precise estimate of total average impact rather 
than changes in distribution of those impacts.  
 
This approach will work if the dimensions of risk and equity heterogeneity are completely 
independent. Influenza risk is not related to geography, so that if a policy-maker wishes to 
consider the consequence of a national vaccination programme on regional inequity, then the 
distribution of benefit between regions can be done after the national analysis of the impact of 
vaccination. Although it is probably quite rare for heterogeneity and equity dimensions to be 
completely independent, in reality, this approach might be useful given its relative ease. In 
particular, the data requirements for this approach are relatively light. 
 
Cases distributed through equity dimension(s) with parallel unlinked models 
The next approach to dynamic transmission equity analysis considered is to group the population 
by equity strata prior to the simulation of disease transmission. Here, the transmission model is 
run in parallel for each equity group. Groups are assigned a prior risk of infection and simulations 
may be run with or without interventions, i.e. distributing interventions unevenly across the 
equity strata could be a policy option.  
 
The added advantage of a series of parallel models compared to post-simulation assumptions 
about the distribution of cases by equity related sub-groups is that there are non-linearities in 
how different levels of disease transmission might respond to interventions. This approach 
therefore includes the differing effects of reduced transmission in different population sub-
groups, resulting in a different post-simulation distribution of disease burden.  
 
To continue the influenza example, mortality is related to pre-existing conditions, such as chronic 
obstructive pulmonary disease, which are not uniformly distributed geographically. A policy-
maker might wish to include regional specific outcomes by running the transmission dynamic 
model for each region separately. Such an approach might demonstrate that differential 
targeting of different regions reduces the inequity in mortality risk between regions. 
As with the previous approach, considering multiple separate populations could be a pragmatic 
approach to equity analysis as existing transmission models may be used. The separate models 
can be parameterised differently, if say the age-related contact structure differs between equity 
sub-groups, so there are additional data requirements to determine if this is necessary. However, 
it may be less common to explore policy questions where it may be accurate to consider each 
equity sub-group as entirely separate, with no transmission of infection between sub-groups.  
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Figure 2: Equity-related heterogeneity is propagated through parallel transmission models 
 
 
 
Cases distributed through equity dimension(s) integrated into model – independent risk and equity 
heterogeneities 
In many cases, it will be important to consider transmission between equity-defined sub-groups 
in order to capture accurately the distributional outcomes of interventions. In order to relax the 
assumption of independent sub-groups we need to introduce a contact matrix which specifies 
the degree of transmission that occurs within sub-groups and between them. That is, an 
infectious individual in sub-group A infects other individuals in sub-group A at a certain rate and 
infects individuals in sub-group B at a different rate. Note that the transmission models in each 
of the previous approaches will likely already include a contact matrix for the risk heterogeneity 
dimension(s), so that the requirement here is for an additional contact structure. The approach 
has the benefit of more accurately capturing the indirect impacts of interventions targeted at 
different equity-defined sub-groups. It may be justifiable to provide services selectively to 
disadvantaged groups, not only because of equity principle but because the wider population 
also benefits substantially through reduced risk. 
 
To continue the influenza example, it might become clear that it is no longer possible to assume 
that geographical regions of interest can be considered as epidemiologically separate – for 
example, if there is significant daily commuter traffic between regions. In this case, vaccination 
in one region will influence the transmission in another region. 
 
Adding additional dimensions to transmission dynamic models adds significant complexity, 
particularly with respect to defining and estimating contact matrices. For example, to incorporate 
a single equity dimension such as household income with n strata will require n2 additional 
parameters (or assumptions). Note that the implicit assumption in this framework is that the 
equity and heterogeneity dimensions remain independent – individuals can be infected from 
other heterogeneity groups or risk strata such that infection from other strata does not depend 
on their heterogeneity group. 
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Figure 3: Equity-related heterogeneity is integrated into transmission model 
 
 
 
Cases distributed through equity dimension(s) integrated into model – correlated risk and equity 
heterogeneities 
Each of the previous approaches makes the assumption of no interaction between the two 
dimensions of heterogeneity (risk and equity). A model considering a correlation between risk 
and equity dimensions will allow separate contact rates for all of the heterogeneity 
compartments. To continue the influenza example, this approach allows the model to have 
specific contact rates for individuals by both risk and equity heterogeneity groups, reflecting that 
the daily commuting between regions is, say, age-specific. 
 
It will be important to consider whether this complexity will be required to answer the policy 
questions of interest. While the model structure should represent realistic mechanisms and 
interactions, unnecessary complexity should be avoided. Parameterisation and validation of a 
model becomes more complex if models have to include multiple dimensions of risk 
heterogeneity (e.g. age, gender and sexual behaviour) and equity heterogeneity (e.g. household 
income, ethnicity and region). This complexity is likely to be the greatest barrier to combining 
equity economic evaluation frameworks designed to compare multiple dimensions of 
heterogeneity, such as Distributional Cost Effectiveness Analysis (DCEA), with transmission 
dynamic models. 
 
The majority of transmission models have been based on compartmental models, in which the 
population is divided up into groups based on their risk of infection, risk of disease and infection 
status. The model framework (typically differential equations) then determines the flow of 
individuals between compartments. However, if equity dimensions and differential uptake 
(perhaps on a different dimension) are included, then this approach becomes increasingly 
unwieldy. If the size of compartments become small (<30 individuals), then stochastic effects can 
become important. This creates a push towards individual-based, stochastic models (68). 
Technically, the issues of solving, parameterising, and validating such models is far from an exact 
science, although there has been considerable recent progress (69,70). As the models become 
more complex, the number of possible model structures increases. This has led to increasing 
 29 
 
formation of model comparison exercises and consortia to try and understand and account for 
structural uncertainty in decision-making (71–76). 
 
Data requirements 
The choice of which (risk or equity) heterogeneity dimensions to include in a model depend on 
the societal view of the importance of potential differences, logical consistency of the model 
structure in relation to known epidemiology, and the data available to parameterise them. 
However, it is impossible for models to have complete accuracy, and many of the risk 
heterogeneity groupings included are surrogates for highly correlated variables. For example, 
including age as a heterogeneity in models of childhood viral infections actually stands for school 
attendance, and adults working in schools are not specifically included. Further, the risk and 
equity dimensions are likely to be linked through combinations of causality, correlation, and 
confounding. For example, if household income is related to number of children, then income 
status is related to age, which is related to schooling and infection risk. Such complexity is very 
common, which is why we suggest that, depending on the policy question, the first three model 
structure approaches are less likely to be sufficient. 
 
Box 2: Differential placement of Xpert MTB/RIF 
What is the problem? To illustrate the impact of heterogeneity definitions on recommendations 
What do we know already? The placement of Xpert MTB/RIF (a new point-of-care diagnostic tool of 
tuberculosis) at lower levels of health system is expected to improve access to diagnostics in difficult-to-
access settings (equity) at higher costs. Exploring the epidemiological impact of universal access to rapid 
tuberculosis diagnosis using agent-based simulation. Conference: 2017 Winter Simulation Conference 
(WSC) (40).  
What will this illustration add? We propose to explore two scenarios based on different assumptions of 
correlation between risk and equity distributions: 1) no correlation: high and low TB risk groups distributed 
homogeneously across urban and rural settings; and 2) Correlation: the distribution of TB risk is correlated 
to the setting (urban populations are also at higher risk). This illustration will help understand how the 
inclusion of a correlation between distributions of risk and equity dimensions change the nature and size of 
efficiency/equity trade-offs in economic evaluations. 
What would be the relevant message for the following stakeholders?  
1) national and regional governments/payers: this example will help illustrate the uncertainty related 
to data availability when presenting the trade-off between CE and equity considerations  
2) global donors/development partners: as above 
3) researchers in LMICS and HICs: there are key methods and data needs considerations on how to 
approach an equity-efficiency trade off analysis as well as the development of communication 
tools to inform effectively decisions will be discussed.   
4) iDSI : we will aim to use this example to illustrate the data considerations when applying the 
reference case to economic evaluations 
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As the model and equity analysis become more complex, the data required to support the 
analysis can become very great (see text box 3). The standard data needs for a transmission 
model are: 
1. Direct estimates of some parameters (e.g. demographic estimates of population size) 
2. Training data used to fit the model, including incidence or prevalence of infection/disease in the 
same dimensions as the model (i.e. including all the heterogeneity and equity groups at least as 
marginal distributions) 
3. Validation data used to check the model performs as expected and includes data different from 
the training data 
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All parameters used in the model must be specified using appropriate sources or fitted, and it is 
critical for complex models that the uncertainty in parameter values is carried forward through 
all subsequent stages of analysis, which usually implies a Bayesian approach.  
 
As we introduce heterogeneity into a homogenous model, data will then be required to describe 
this structure. To divide a homogeneous population into sub-groups we need to know the 
population in each group and whether any of the model parameters differ between groups. 
These are the minimum data requirements for Approach 2. For Approach 3 and above we must 
also obtain data on (or make assumptions about) the extent to which each group is connected 
with the other groups. In addition, it will be important to consider the extent to which there are 
correlations between parameter changes between groups. For example, baseline immunity may 
Box 3: Contact data requirements 
Let 𝛽ሺ𝑖, 𝑗ሻ be the contact rate between groups i and j in the risk dimensions, and 𝜑ሺ𝑎, 𝑏ሻ be 
the contact rate between groups a and b in the equity dimensions. Suppose there are n risk 
groups and m equity groups.  
 
Then in the first approach only 𝛽ሺ𝑖, 𝑗ሻ is defined, which has n2 elements.  
 
In the second approach, it is possible to define 𝛽ሺ𝑖, 𝑗ሻ for each equity group, 𝛽ሺ𝑖, 𝑗, 𝑎ሻ but 
𝜑ሺ𝑎, 𝑏ሻ is undefined. The extended contact matrix has m.n2 elements. 
 
In the third approach 𝛽ሺ𝑖, 𝑗, 𝑎ሻ and 𝜑ሺ𝑎, 𝑏ሻ  are both defined and the risk of infection for an 
individual in risk dimension i and equity dimension a is given as: 
𝜆ሺ𝑖, 𝑎ሻ ∝෍ 𝛽ሺ𝑖, 𝑗, 𝑎ሻ
𝑗
+෍ 𝜑ሺ𝑎, 𝑏ሻ
𝑏
 
The maximum number of elements (i.e. parameters) for this structure is m.n2 + m2.  
 
In the fourth, and most complicated approach, the rates of infection between individuals are 
defined jointly by their risk and equity heterogeneity: 
𝜆ሺ𝑖, 𝑎ሻ ∝෍ ෍ 𝜌ሺ𝑖, 𝑗, 𝑎, 𝑏ሻ
𝑏𝑗
 
where 𝜌ሺ𝑖, 𝑗, 𝑎, 𝑏ሻ is the contact rate between an individual in risk group i and equity group a 
with an individual in risk group j and equity group b. The maximum number of separate 
parameters is n2 m2. 
 
To give numerical reality, if we have 5 heterogeneity groups and 3 equity strata, then the 
maximum number of parameters for each of the four approaches is 25, 75, 84 and 225 
respectively. 
 32 
 
be correlated with baseline risk of infection and these may or may not be correlated with equity-
related heterogeneity of interest.  
 
In summary, the data considerations (to be obtained or fitted) when defining changes to model 
heterogeneity are: 
1. Data to describe the distribution of population in each sub-group – equity and risk heterogeneity 
2. Changes in model parameter values between groups, for example assuming access to treatment 
changes by sub-group. 
3. Data to parameterise correlations between heterogeneity dimensions  
4. Data to characterise between-group connectivity 
We summarise these model typologies in Table 5 and consider differences in terms of 
improvements to quantifying equity impacts and with respect to the key domains that determine 
transmission dynamics.  
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Table 5: Summary of methodological approaches to using disease transmission models to assess equity in economic evaluations  
Analytic approach Summary Equity-related data 
requirements 
Transmission model with 
post-simulation 
distribution of cases 
across equity sub-groups 
The distribution of risk after modelling the impact of an intervention is assumed 
to be the same as before. The total impact, including impact due to reduced 
transmission, is estimated by the model but the proportional reduction in risk 
and disease burden is assumed to be equal in all sub-groups.  
This approach is limited in that transmission dynamics of equity related sub-
groups are not modelled. The approach does include some estimate of the total 
impact on transmission but with respect to distributional changes is similar to 
the application of static models. 
The pre-intervention 
distribution of infection or 
disease between equity sub-
groups  
Unlinked parallel 
transmission models for 
each equity-related sub-
group 
As above, this approach still requires minimal adaptation of the transmission 
model but includes the ability to estimate nonlinearities between how equity 
sub-groups may respond to interventions. However, important limitations 
remain. 
Each equity-related sub-group is treated as a separated population and non-
linearities in the relationship between interventions and their effect on 
transmission are simulated. Unlike the above example, this means that the post-
simulation distribution of disease burden across equity sub-groups may differ 
from prior information on the distribution of risk. 
This approach implicitly assumes a mixing pattern where within equity sub-group 
mixing in homogeneous and between equity – sub-group mixing is zero. The 
major limitation of this approach is that this might be an epidemiologically 
unacceptable assumption. 
The distribution of infection 
or disease between equity 
sub-groups (applied as an 
input to the model rather 
than to the output as above). 
Any sub-group specific 
transmission model 
parameterisation. For 
example, reduced access to 
treatment or greater 
likelihood of infection from 
an infectious contact, among 
low-income groups. 
Equity related 
heterogeneity is 
integrated into the 
transmission model but 
not structurally linked 
with risk related 
heterogeneity 
As above, each equity sub-group is assigned a transmission sub-model with 
group specific prior information on risk. However, in this case a contact matrix is 
defined which specifies contact probabilities between different equity sub-
groups. Structurally this is more realistic than the previous “island populations” 
approach but obtaining data on the contact between equity groups can be a 
challenge. 
It may be important to include between group contacts if modelling strategies 
for targeting the intervention to one or more equity sub-groups. For example, 
As above plus a contact 
matrix to allow (unequal) 
transmission between equity 
sub-groups. 
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targeting equity groups with high disease risk may also reduce transmission 
among groups not receiving the intervention.  
Equity related 
heterogeneity is 
integrated into the 
transmission model and 
structurally linked with 
risk related heterogeneity 
In this, most comprehensive, approach, contact heterogeneities are fully 
integrated and quantified.  
 
As above with a 
comprehensive contact 
matrix relating all risk and 
equity sub-groups to each 
other 
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In this section, we highlighted that while heterogeneity in certain characteristics such as age 
or sex is commonly found in disease transmission models, many characteristics that may be 
relevant to equity analysis are not. We go on to outline a spectrum of approaches that are 
available when using disease transmission models to estimate healthcare costs and effects 
across sub-populations of interest and highlight the substantial data needs of integrating 
heterogeneity into the transmission model. There is a balance between model and analytical 
simplicity, parsimony, and practicality against precision of results. Where this balance lies is 
likely to depend on the specifics of the policy question. 
 
Interpretation and reporting of results 
Consideration should be given to the presentation of results depending on the equity 
question with emphasis to facilitating the relaying of information and not pre-empting the 
decision to be made. We could envisage a descriptive presentation of distribution of benefits 
across both equity and risk dimensions or should we be interested in a trade-off analysis, it 
might be important to illustrate the magnitude of these trade-offs using scenario analyses. 
Further research might be needed to develop aggregate value scores as an integrated 
representation of the risk-efficiency-equity interaction.  
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Recommendations 
We summarise the analytical process of including equity in transmission based economic 
evaluations as a set of steps. In line with the IDSI Reference Case guidance, we discussed the 
methodological considerations at the different steps suggested. These are tools to guide the 
analysts own decision making, rather than a prescriptive set of specifications. These guidance 
steps are a first draft and will be reviewed by participants of the workshop. 
 
Table 6: Consideration checklist for analysts considering equity-informed economic evaluation using a disease 
transmission model 
Domain Considerations 
Policy question  Perspective of decision maker 
Equity principle of interest 
Sub-groups of interest 
 
Evaluation 
framework 
Outcome of interest 
Analytical approach  
 
Model structure  
 
Heterogeneity dimensions 
Level of integration of risk and equity dimensions 
 
Data needs Description of distributions across equity and risk heterogeneity 
Parameterisation of correlations between heterogeneity dimensions  
Characterisation of between-group connectivity 
 
Interpretation and 
reporting of results 
Description of distribution of (direct and indirect) effects and costs 
Visualisation of trade-offs between equity, risk, and efficiency 
Aggregate value score 
 
 
For example, a decision problem relating to providing healthcare insurance for people living 
below the poverty line has a clear pre-specified group of interest and an equity goal to provide 
a decent minimum standard of care and maximise benefits for the least advantaged 
(Rawlsian). In turn this suggests that key metrics will include health gains and financial 
protection, the key dimension of heterogeneity will be socio-economic status and the most 
appropriate framework could be ECEA. The model design and data requirements will depend 
on the specifics of the study question, whether developed transmission models exist, whether 
data are available as well as the time and resources available.  
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